GOSS
HEALTHCAREGossamer Bio Inc
$0.35+0.01 (+4.23%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GOSS Today?
No stock-specific AI insight has been generated for GOSS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.32$3.87
$0.35
Fundamentals
Market Cap$82M
P/E Ratio—
EPS$-0.75
Dividend Yield—
Dividend / Share—
ROE-7.8%
Profit Margin—
Debt / Equity—
Trading
Volume4.6M
Avg Volume (10D)—
Shares Outstanding234.7M
GOSS News
37 articles- CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallSt – Company Announcement - FT.comFinancial Times·May 7, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages zSpace Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZSPCGlobeNewswire Inc.·Apr 28, 2026
- INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens BermanGlobeNewswire Inc.·Apr 28, 2026
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSSGlobeNewswire Inc.·Apr 28, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 27, 2026
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSSGlobeNewswire Inc.·Apr 24, 2026
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages zSpace Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZSPCGlobeNewswire Inc.·Apr 24, 2026
- How Mixed Trial Results And Balance Sheet Pressure Are Reframing The Gossamer Bio (GOSS) StoryYahoo Finance·Apr 23, 2026
- Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens BermanGlobeNewswire Inc.·Apr 23, 2026
- DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsGlobeNewswire Inc.·Apr 20, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 20, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 16, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 16, 2026
- COTY Investor Alert: Coty Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misled on Growth Timeline: Levi & KorsinskyGlobeNewswire Inc.·Apr 13, 2026
- Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc.·Apr 13, 2026
- Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 SetbackYahoo Finance·Apr 12, 2026
- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsightGlobeNewswire Inc.·Apr 8, 2026
- Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to NeutralYahoo Finance·Apr 7, 2026
- Holzer & Holzer, LLC Reminds Investors of June 1, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against New Era Energy & Digital, Inc. (NUAI) and Gossamer Bio, Inc. (GOSS)GlobeNewswire Inc.·Apr 6, 2026
- Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (GOSS)GlobeNewswire Inc.·Apr 1, 2026
- Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA SetbackYahoo Finance·Mar 30, 2026
- Gossamer Bio (GOSS) Continues Downtrend Despite Impressive RevenueYahoo Finance·Mar 24, 2026
- Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory EnvironmentYahoo Finance·Mar 20, 2026
- Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 17, 2026
- Gossamer Bio: Q4 Earnings SnapshotYahoo Finance·Mar 17, 2026
- Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 17, 2026
- Gossamer Bio options imply 46.1% move in share price post-earningsYahoo Finance·Mar 13, 2026
- Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseYahoo Finance·Mar 9, 2026
- How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street ValuationsYahoo Finance·Mar 9, 2026
- Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1Yahoo Finance·Mar 7, 2026
- Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to DeclineYahoo Finance·Mar 5, 2026
- Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Feb 26, 2026
- Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock NowYahoo Finance·Feb 26, 2026
- Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo Finance·Feb 26, 2026
- BC-Most Active StocksYahoo Finance·Feb 25, 2026
- Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial HypertensionYahoo Finance·Feb 25, 2026
All 37 articles loaded
Price Data
Open$0.34
Previous Close$0.34
Day High$0.36
Day Low$0.33
52 Week High$3.87
52 Week Low$0.32
52-Week Range
$0.32$3.87
$0.35
Fundamentals
Market Cap$82M
P/E Ratio—
EPS$-0.75
Dividend Yield—
Dividend / Share—
ROE-7.8%
Profit Margin—
Debt / Equity—
Trading
Volume4.6M
Avg Volume (10D)—
Shares Outstanding234.7M
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—